


FULL VALUE BEEF™

How to Prepare for the
Veterinary Feed Directive
(VFD)


Montana Nutrition Conference and
Livestock Forum April 28-29, 2015

Bruce W. Hoffman, DVM
Technical Consultant
Beef Business Unit

USBBUMUL00865




1



**BETTER
TOGETHER:**

The Journey Begins



A Robust Portfolio

Health Management Products

Vaccines

ARSENAL® 4.1 **BOVINE ECOLIZER®+C20** **Bovine Pili Shield®** **BRD SHIELD®**

BVD Shield® 3 **Clostridium Perfringens Type A Toxoid** **Clostratox®**

Clostri Shield® **Fusogard®** **Master Guard**

PINK EYE SHIELD® XT4 **Quick Shield®** **ReproSTAR®** **NUPLURA PH**

Somnu Shield® **Titanium** **Vib Shield® Plus L5** **SCOUR BOS®** **VIRA SHIELD®**

Antibiotics & Parasiticides

Micotil **Pulmotil** **StandGuard**

Feed Optimization Products

HeifermaX 500 **Rumensin** **Tylan**

End-point Management Products

Component **Compudose** **Encore** **Optaflexx**

Micotil® (tilmicosin injection) is approved for the treatment and control of BRD.

FULL VALUE BEEF USBBUMUL01166 **Elanco** 3


The Good News

- **Today**, antibiotics used in farm animals are not top-of-mind
- Few think about them as they shop for food

USBBUMUL00865 7

2013 International Consumer Attitudes Study (ICAS)

2nd Edition: May 2013



USBBUMUL00865

10

Consumer Concerns

Antibiotic use, among other things, makes consumers uncomfortable.

1-10 scale; percent responding "uncomfortable" (1-3)	Total	Food communicators	"I'm not aware of this method"
Supplementing naturally occurring animal hormones	55%	72%	2%
Using dihydrogen monoxidization (H ₂ O) on crops & farm animals	52%	53%	14%
Using pesticides on crops	49%	59%	1%
Administering animal antibiotics	48%	61%	1%
Using genetically modified (GMOs) or biotech seeds	43%	51%	2%
Using fertilizers on crops	26%	31%	—

USBBUMUL00865 Source: ml&p research for USFRA, 10/11, n=1,400

14

Consumer Concerns

Antibiotic use, among other things, makes consumers uncomfortable.

1-10 scale; percent responding "uncomfortable" (1-3)	Total	Food communicators	"I'm not aware of this method"
Supplementing naturally occurring animal hormones	55%	72%	2%
Using dihydrogen monoxidization (H ₂ O) on crops and farm animals	52%	53%	14%
Using pesticides on crops	49%	59%	1%
Administering animal antibiotics	48%	61%	1%
Using genetically modified (GMOs) or biotech seeds	43%	51%	2%
Using fertilizers on crops	26%	31%	—

USBBUMUL00865 Source: ml&p research for USFRA, 10/11, n=1,400

15



FULL VALUE BEEF™

The Challenge...

It's not what you say, it's what they hear.



USBBUMUL00865

17

The Disconnect

YOU SAY	THEY HEAR
We use antibiotics to be more efficient.	Because you only care about making money...
We use antibiotics to keep animals healthy.	You HAVE to use antibiotics because animals are kept in poor conditions.
Regulatory agency reviews have approved antibiotics as safe after rigorous review processes.	We don't know if it's safe for the long term. They've been wrong before...
There are rules that dictate maximum residue levels allowed in animals.	How can we be sure ANY residue is safe?
There is no evidence that use of antibiotics in animals causes resistance in humans.	Yeah right. We're using so many, that has to be part of the reason.

USBBUMUL00865

18

What Do We Do?

- In a world where our audience doesn't **TRUST**
 - That antibiotics are safe
 - That they're used judiciously
 - That they're used for the right reasons

USBBUMUL00865

19

Rebuilding Trust in Antibiotics

- Acknowledge concerns
- Accept responsibility
- Add context
- Align language

USBBUMUL00865

22

Access to Antibiotics

- A public health issue
- Access to effective antibiotics



Critical for public health



Vital for livestock & poultry production




Essential for animal well-being

USBBUMUL00865

24

FDA Releases Antibiotic Guidance

- FDA goal: protect human health & curb development of antimicrobial resistance
- 3 proposed documents to modify use of medically-important antibiotics in food producing animals




USBBUMUL00865

25

Compliance Timeline

- FDA pursuing voluntary compliance
- FDA to evaluate progress 3 years after final publication
 - Guidance for Industry #213 finalized Dec. 2013
 - FDA will consider “further actions” as warranted



USBBUMUL00865

26

Implications

- Food producers aren't losing all feed-grade antibiotics
- The way they're used will change
- Key phrase is “medically-important”
 - Refers to drugs important for therapeutic use in humans



USBBUMUL00865

28


Three Classes of Antibiotics

- **Human-only antibiotics** are not approved for use in animals, creating a reserve of unique antibiotics for human health needs
- Because animals are susceptible to different diseases & have different needs than humans, **animal-only antibiotics** have been developed to treat specific health requirements of animals & are not used in human medicine
- **Shared-class antibiotics** are approved for animals & humans. Going forward, Elanco will only promote this class of antibiotics for therapeutic uses in animals under veterinarian supervision

USBBUMUL00865

29

FDA/CVM (GFI #209) Will Phase Out Performance Indications for Certain Antibiotics



What Will Change?

Antibiotic classes	Animal-only	Shared-use
Performance	Ionophore — ADG/FE Bambermycin — ADG	CTC — ADG/FE
Prevention	Ionophore — Coccidiosis	Oxytetracycline — SFC
Control	Ionophore — Coccidiosis Carbodox — dysentery	Tylan — Liver abscess CTC — Pneumonia CTC — Liver abscess CTC — Anaplasmosis
Treatment	Tiamulin — dysentery	CTC — Enteritis

= No longer allowed
 = VFD required

USBBUMUL00865

37

Establishment of VFDs

- First passed in 1996 (ADAA; 21 CFR 558)
- Requires a coordinated effort: producer, veterinarian, nutritionist & feed supplier
 - Requires veterinary oversight of feed use antimicrobials
 - **Written statement (VFD form)** by licensed veterinarian that authorizes client/producer to obtain & use (on designated products)
 - Follow “Standards of Practice” in state where cattle reside. Drops the requirement for VCPR

USBBUMUL00865

38

Modernizing VFD

- GFI #209 proposed to modernize & add “shared-class” products
- *This raised concerns....*
 - Limited experience with VFD process
 - Logistical & administrative burden
 - Access to veterinarians
 - Increased cost (producer, vet, feedmills)

USBBUMUL00865

39

Veterinarian Use & Oversight

- Each product approved under the VFD regulations includes the following caution:

CAUTION: Federal law limits this drug to use under the professional supervision of a licensed veterinarian. Animal feed bearing or containing this veterinary feed directive drug shall be fed to animals only by or upon a lawful veterinary feed directive issued by a licensed veterinarian in the course of the veterinarian's professional practice.

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

USBBUMUL00865


41


VFD Regulations on Distribution

- One-time Notifications
 - Notice to FDA of distribution of VFD feeds
 - Notification to FDA that you intend to handle/distribute VFD drug-containing medicated feeds
 - Acknowledgement of distribution limitations for VFD feeds
 - Document stating that the purchasers will sell the VFD feeds only to producers with valid VFD orders or to other distributors for whom they have acknowledgement notices

USBBUMUL00865

44





083251

Pulmotil® (tilmicosin) Veterinary Feed Directive for use in Cattle

Client: _____ Veterinarian: _____
 Address: _____ Address: _____
 Phone #: _____ Phone #: _____
 Fax #: _____ Fax #: _____

Cattle to be treated (number and location):	Special Instructions:
---	-----------------------

Mix into Type C Medicated Feed to Provide:

_____ total lbs Type C Complete feed at _____ g/ton
Type C complete feed range of 568 to 757 g/ton (100% Dry Matter Basis)

Month/Day/Year (not to exceed 45 days) _____

Amount of final (Type C) feed: _____

Complete this additional line to adjust the amount of tilmicosin included in Type C Complete feed during the 14 day administration period

_____ total lbs Type C Complete feed at _____ g/ton
Type C complete feed range of 568 to 757 g/ton (100% Dry Matter Basis)

Veterinarian's signature: _____
 Date: _____ License # and State _____

☐ Initial this box if you would like to use this VFD order to authorize the feeding of this tilmicosin medicated animal feed in an FDA approved combination of tilmicosin with other drug(s). If so, you are required to provide the information on the other drug(s) in such drug combination in the following table.

Drug (Ingredient)	Drug Level or Any Special Instructions	Initial

Home - GlobalVetLink
www.globalvetlink.com

GlobalVetLINK

INNOVATIVE DIGITAL SOLUTIONS FOR ANIMAL HEALTH

[PRESS ROOM](#) | [RESOURCE CENTER](#) | [CAREERS](#) | [LOGIN/SIGN UP](#)

[Home](#) | [About Us](#) | [Our Solutions](#) | [Our Customers](#) | [Industry Partners](#) | [Contact](#)

INTRODUCING THE NEW

FeedLINK™ SYSTEM!

Providing an electronic Veterinary Feed Directive (eVFD) System that allows secure, faster fulfillment and tracking of VFD prescriptions. It uniquely connects the veterinarian to various animal health industry stakeholders to improve animal health and safety.

CustomerSPOTLIGHT

COLIN KIRKEGAARD, DVM

"The new FeedLINK eVFD system is much more intuitive and it's faster and bounds better than the old eVFD system! The work flow resembles how you need!"

Latest News

GoPass Available to Virginia Vets

Mobile-Friendly for the Traveling Vet!

GVL clients can access the system from anywhere with an internet connection, allowing for easy creation of electronic health documents in the field.

- Visit globalvetlink.com to get started
- Click "Login/Sign Up" in the top-right corner to create a new account or to sign in

feedstuffs.com/vfd

USBBUMUL00865

51

Key Points: Feed Antibiotics & VFD

- Coordinated effort, but still allow judicious use of medically-important antibiotics
 - One-time notification
 - Require vet oversight
 - Pen or group animal detail
 - Written or electronic form authorization
- Effort to protect human & animal health & secure food safety

Investing in Innovation



Pursue
advances &
treatments that
lessen reliance
on antibiotics



Seek new
therapeutic
indications for
treatment, control
& prevention of
diseases



Support use of
antimicrobials
used only in
animals for growth
& performance
(where permitted)



Provide services
that help verify
& validate
responsible
product use

USBBUMUL00865

59



FULL VALUE BEEF™

Thank You



USBBUMUL00865



60

BMD and Albac are registered trademarks of Alpharma Inc.
 Flavomycin is a registered trademark of Huvepharma AD.
 Mecadox and Vmax are registered trademarks of Phibro Animal Health Corporation
 Denagard is a registered trademark of Novartis.
 Neomix is a registered trademark of Pharmacia & Upjohn Animal Health.
 Lincomix and LA-200 are the property of Zoetis Inc., its affiliates and/or its licensors.

Elanco®, Coban®, Hygromix®, Maxiban®, Monteban®, Rumensin®, Skycis®, Tylan® and the diagonal bars are all trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

© 2014 Elanco Animal Health. All rights reserved.

All other trademarks are the property of their respective owners.

USBBUMUL00865

61

How to use Tylan® premix for swine

For ileitis control:	Recommendation:
Feed Tylan at 100 g/ton for at least 3 weeks, followed by 40 g/ton to market weight.	Begin feeding Tylan at 12-15 weeks of age or 3 weeks prior to seroconversion, ^{1,2} because gross or microscopic lesions appear well in advance of seroconversion/disease.

* No withdrawal required when fed according to label directions.

How to use Tylan Soluble for swine

Swine: For the treatment and control of swine dysentery, medicate with 250 mg tylosin per gallon in drinking water for 3 to 10 days, depending upon severity of infection. Alternatively, medicate with 250 mg tylosin per gallon in drinking water for 3 to 10 days, followed by 40 to 100 g tylosin per ton of complete feed (Type C medicated feed manufactured from TYLAN Type A medicated article) for 2 to 6 weeks. For control of porcine proliferative enteropathies (PPE, ileitis), medicate with 250 mg tylosin per gallon in drinking water for 3 to 10 days, followed by 40 to 100 g tylosin per ton of complete feed (Type C medicated feed manufactured from TYLAN Type A medicated article) for 2 to 6 weeks. Swine must consume enough medicated water to provide a therapeutic dose. Only medicated water (250 mg tylosin per gallon) should be available while medicating with TYLAN Soluble.

RESIDUE WARNING: Swine must not be slaughtered for food within 48 hours after treatment.

1. Guedes, R. 2004. "Update on epidemiology and diagnosis of porcine proliferative enteropathy." J. Swine Health Prod. 12(3): 134-138.
 2. Ambruster, G., et al. 2007. "Review of Lawsonia intracellularis seroprevalence screening in the United States, June 2003 to July 2006." AASV Proc.: 231-233.

USBBUMUL00865

62

How to use Tylan® premix for broilers and breeders

- For increased rate of weight gain feed Tylan at:
 - Tylan 40 per ton of Type C feed: 0.1 to 1.25 lbs.
 - Tylosin per ton of Type C feed: 4 to 50 g
- To aid in the control of chronic respiratory disease associated with *Mycoplasma gallisepticum*:
 - Tylan 40 per ton of Type C feed: 20 to 25 lbs.
 - Tylosin per ton of Type C feed: 800 to 1,000 g
- Feed continuously as the sole ration.
- Tylan requires a 5-day withdrawal period before slaughter when fed at 800-1,000 g/ton.

How to use Tylan Soluble for broilers

- As an aid in the treatment of chronic respiratory disease (CRD) caused by *Mycoplasma gallisepticum* sensitive to tylosin in broiler and replacement chickens. For the control of chronic respiratory disease (CRD) caused by *Mycoplasma gallisepticum* sensitive to tylosin at time of vaccination or other stress in chickens. For the control of chronic respiratory disease (CRD) caused by *Mycoplasma synoviae* sensitive to tylosin in broiler chickens.
- Chickens should be treated for 3 days; however, treatment may be administered for 1 to 5 days depending upon severity of infection. Treated chickens must consume enough medicated water to provide 50 mg/lb. of body weight per day. Only medicated water should be available to the birds.

How to use Tylan Soluble for turkeys

- For maintaining weight gain and feed efficiency in the presence of infectious sinusitis caused by *Mycoplasma gallisepticum* sensitive to tylosin.
- Turkeys should be treated for 3 days; however, treatment may be administered for 2 to 5 days depending upon the severity of infection. Treated turkeys must consume enough medicated water to provide 60 mg/lb. of body weight per day. Only medicated water should be available to the birds.

USBBUMUL00865

63

How to use Tylan® Premix for beef cattle

- For reduction of incidence of liver abscesses associated with *Fusobacterium necrophorum* and *Arcanobacterium pyogenes*:
 - Feed tylosin continuously at 8-10 g/ton (90% DM) to deliver 60-90 mg/hd/d.

Hygromix® directions for use

- For use as an aid in the control of parasite infections in chickens associated with *Ascaris galli*, *Heterakis gallinae* and *Capillaria obsignata*.
- Mix 1.0-1.5 lbs. Hygromix 8 per ton of Type C medicated feed for 8-12 g of hygromycin B per ton.
- Feeds containing Hygromix must be withdrawn 3 days prior to slaughter.

Recommendation^{1,2}

Feed to pullets and breeders at 12 g/ton from placement through 50 weeks.

The labels contain complete use information, including cautions and warnings.
Always read, understand and follow the label and use directions.

1. Eckman, M. 1998. "Controlling Helminth Parasites in Layer, Broiler Breeder Flocks." Poultry Sci. June/July.

2. Shumard, R., et al. "Hygromycin B: An Anthelmintic for Effective Control of Nematode Parasites of Chickens." Symposium of Tylan and Hygromix.

USBBUMUL00865

64

Coban® for broilers and breeders

- For coccidiosis prevention, feed Coban at 90-110 g/ton.
 - Feed continuously as the sole ration.
 - Requires a zero-day withdrawal (when fed according to the label).
- CAUTION: Ingestion of monensin by horses and guinea fowl has been fatal.**

Coban® for turkeys

- For coccidiosis prevention, feed Coban at 54-90 g/ton.
 - Feed continuously as the sole ration.
 - Requires a zero-day withdrawal (when fed according to the label).
- CAUTION: Ingestion of monensin by horses and guinea fowl has been fatal.**

Skycis® Indications	Appropriate concentrations of narasin in Type C Medicated Feed
Increased rate of weight gain in growing-finishing swine when fed for at least 4 weeks.	13.6 to 27.2 g/ton (15 ppm to 30 ppm)
Increased rate of weight gain and improved feed efficiency in growing-finishing swine when fed for at least 4 weeks.	18.1 to 27.2 g/ton (20 ppm to 30 ppm)
No increased benefit in rate of weight gain has been shown when narasin concentrations in the diet are greater than 13.6 g/ton (15 ppm).	
No withdrawal period is required when used according to the label.	

Cautions:

- Swine being fed with Skycis (narasin) should not have access to feeds containing pleuromutilins (e.g., tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.
- Do not allow adult turkeys, horses or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals.

USBBUMUL00865

65

Maxiban® directions for use

- For coccidiosis prevention, feed Maxiban at 54-90 g/ton.
 - Feed continuously as the sole ration.
 - Requires a 5-day withdrawal.
- CAUTION: Ingestion of narasin by adult turkeys, horses or other equine species has been fatal. Do not feed to laying hens.**

Monteban® directions for use

- For coccidiosis prevention, feed Monteban at 54-90 g/ton.
 - Feed continuously as the sole ration.
 - Requires a zero-day withdrawal (when fed according to label).
- CAUTION: Ingestion of narasin by adult turkeys, horses or other equine species has been fatal. Do not feed to laying hens.**

Rumensin® directions for use

Consumption by unapproved species or feeding undiluted may be toxic or fatal. Do not feed to veal calves.

Dairy Cow: For increased milk production efficiency (production of marketable solids-corrected milk per unit of feed intake):
Total Mixed Rations: Feed continuously to dry and lactating dairy cows a total mixed ration ("complete feed") containing 11 to 22 g/ton monensin on a 100% dry matter basis.
Component Feeding Systems (including top dress): Feed continuously to dry and lactating dairy cows a Type C Medicated Feed containing 11 to 400 g/ton monensin. The Type C Medicated Feed must be fed in a minimum of 1 pound of feed per cow per day to provide 185 to 660 mg/head/day monensin to lactating cows or 115 to 410 mg/head/day monensin to dry cows. This provides cows with similar amounts of monensin they would receive by consuming total mixed rations containing 11 to 22 g/ton monensin on a 100% dry matter basis.
Growing cattle on pasture or in dry lot (Dairy replacement heifers): For increased rate of weight gain: Feed at the rate of not less than 50 nor more than 200 mg/head/day in not less than 1 pound of Type C Medicated Feed; or after the 5th day, feed at the rate of 400 mg/head/day every other day in not less than 2 pounds of Type C Medicated Feed. The monensin concentration in the Type C Medicated Feed must be between 25 and 400 g/ton. During the first 5 days, cattle should receive no more than 100 mg/day contained in not less than 1 pound of feed. Do not self feed.
For the prevention and control of coccidiosis due to *Eimeria bovis* and *Eimeria zuernii*: Feed at a rate to provide 0.14 to 0.42 mg per pound body weight per day, depending upon severity of challenge, up to a maximum of 200 mg/head/day. The monensin concentration in Type C Medicated Feed must be between 25 and 400 g/ton. During the first 5 days, cattle should receive no more than 100 mg/day contained in not less than 1 pound of feed.

USBBUMUL00865

66

Important Safety Information

- **See label on slide 63 for complete use information, including boxed human warnings and non-target species safety information.**
- Micotil is to be used by, or on the order of, a licensed veterinarian. For cattle or sheep, inject subcutaneously. Intravenous use in cattle or sheep will be fatal. Do not use in female dairy cattle 20 months of age or older. Use in lactating dairy cattle or sheep may cause milk residues.
- The following adverse reactions have been reported: in cattle: injection site swelling and inflammation, lameness, collapse, anaphylaxis/anaphylactoid reactions, decreased food and water consumption, and death; in sheep: dyspnea and death.
- Always use proper drug handling procedures to avoid accidental self-injection. Do not use in automatically powered syringes.
- Consult your veterinarian on the safe handling and use of all injectable products prior to administration.
- Micotil has a pre-slaughter withdrawal time of 42 days.

USBBUMUL00865

67

Boxed Warning

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Human Warnings: Not for human use. Injection of this drug in humans has been associated with fatalities. Keep out of reach of children. Do not use in automatically powered syringes. Exercise extreme caution to avoid accidental self-injection. In case of human injection, consult a physician immediately and apply ice or cold pack to injection site while avoiding direct contact with the skin. Emergency medical telephone numbers are 1-800-722-0987 or 1-800-428-4441. Avoid contact with eyes.

Note To The Physician: The cardiovascular system is the target of toxicity and should be monitored closely. Cardiovascular toxicity may be due to calcium channel blockade. In dogs, administration of intravenous calcium offset Micotil-induced tachycardia and negative inotropy (decreased contractility). Dobutamine partially offset the negative inotropic effects induced by Micotil in dogs. β -adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of Micotil in dogs. Epinephrine potentiated lethality of Micotil in pigs. This antibiotic persists in tissues for several days.

USBBUMUL00865

68

AHJ302

NADA 140-099, Approved by FDA

Micotil® 300 Injection*

Tilmicosin Injection, USP

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Dosage: Micotil[®] 300 is a solution of the antibiotic tilmicosin. It contains 300 mg of tilmicosin, USP as tilmicosin phosphate in 25% propylene glycol; phosphoric acid as needed to adjust pH for water injection, Q.S. Tilmicosin, USP is produced semi-synthetically and is in the macrocyclic class of antibiotics.

Indications: Micotil[®] is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni and also for the treatment of ovine respiratory (ORF) associated with Mannheimia haemolytica. Micotil[®] is indicated for the control of respiratory disease in cattle at risk of developing BRD associated with Mannheimia haemolytica.

Dosage and Administration: Inject Subcutaneously in Cattle and Sheep Only. In cattle, administer a single subcutaneous dose of 10 to 20 mg body weight (≥ 1 to 2 mL/kg or 1.5 to 3 mL per 100 lbs). In sheep greater than 50 lbs, administer a single intramuscular dose of 10 mg/kg of body weight (1 mL/kg or 1.5 mL per 100 lbs). Do not inject more than 10 mL per injection site.

If no improvement is noted within 48-hours, the diagnosis should be reevaluated.

For cattle and sheep, injection under the skin in the neck is suggested. If not acceptable, inject in the chest behind the shoulders and over the ribs.

Note: Swelling at the subcutaneous site may occur after injection.

Contraindications: Do not use in automatically powered syringes. Do not administer intravenously to cattle or sheep. Intravenous injection of Micotil[®] has caused severe pulmonary edema and death in calves. Do not administer to animals other than cattle or sheep. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats.

Warnings:

Human Warnings: Not for human use. Injection of this drug in humans has been associated with fatalities. Keep out of reach of children. Do not use in automatically powered syringes. Exercise extreme caution to avoid accidental self-injection. In case of human injection, consult a physician immediately and attempt to wash off or flush with copious amounts of water from the skin. Emergency medical telephone numbers are 1-800-722-9897 or 1-800-428-4441. Avoid contact with eyes.

Notes To The Physician: The cardiovascular system is the target of toxicity and should be monitored closely. Cardiovascular toxicity may be due to calcium channel blockade. In dogs, administration of intravenous cationic Mico-Inject induced tachycardia and negative inotropic (decreased contractility). Edema was observed partially due to the negative inotropic effects of Micotil[®] drugs. Beta-adrenergic antagonists, such as propranolol, exacerbated the negative inotropic of Micotil[®] in dogs. Ephedrine potentiated lethality of Micotil[®] in pigs. This antibiotic persists in tissues for several days.

Advertencias Para El Humano: Este producto no es para uso humano. La inyección de este medicamento al ser humano se ha asociado con muertes. Mantenga fuera del alcance de los niños. No permita que los niños operen automáticamente el inyector. Evite el contacto directo con la piel. En caso de accidente, lávelo con agua abundante. En caso de inyección a un ser humano, consulte a un médico inmediatamente y aplique hielo o una bolsa de hielo sobre el sitio de la inyección, evitando el contacto directo con la piel. Los números de teléfono para emergencias médicas son 1-800-722-9897 o 1-800-428-4441. Evite el contacto con los ojos.

Nota Para El Médico: El sistema cardiovascular es el blanco de la toxicidad y debe vigilarse estrechamente. La toxicidad cardiovascular puede deberse al bloqueo de los canales de calcio. En los perros, la administración intravenosa de calcio compensa la toxicidad y los efectos inotrópicos negativos (reducción de la contractilidad) inducidos por Micotil[®]. Los antagonistas beta-adrenérgicos los efectos inotrópicos negativos inducidos por Micotil[®] en perros. Los antagonistas β -adrenérgicos, como propranolol, exacerban el efecto inotrópico negativo de Micotil[®] en los perros. La efedrina potencia la letalidad de Micotil[®] en cerdos. Este antibiótico persiste en los tejidos por varios días.

Residue Warnings: Animals Intended for human consumption must not be slaughtered within 12 days of the last treatment. Not for use in food animal cattle 25 months of age or younger.

Use of Micotil[®] in this class of cattle may cause milk residues. Not for use in lactating ewes producing milk for human consumption.

For Subcutaneous Use in Cattle and Sheep Only. Do Not Use in Automatically Powered Syringes.

Do Not Pour Subcutaneous or Bovine or Ovine. No Admixture can Jergens Acciones Antimicrobianas. Residuos de medicamentos veterinarios pueden permanecer en leche materna durante 12 días después de la última inyección. No utilizar en vacas lecheras. La reacción química que puede ocurrir al matar a los animales. Los efectos de Micotil[®] en bovino y ovino reproductivo, producción y ganancia de peso no han sido determinados.

Adverse Reactions: The following adverse reactions have been reported post approval: In cattle, injection site swelling and inflammation, lameness, collapse, angioedema/hypertrophic reactions, decreased food and water consumption, and death. In sheep: dyspnea and death.

For a complete listing of adverse reactions to micotil[®] injection reported to the CFM see <http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/ucm055394.htm>

Clinical Pharmacology: A single subcutaneous injection of Micotil[®] at 10 mg/kg of body weight in cattle resulted in peak plasma levels within one hour and detectable levels (0.07 $\mu\text{g/mL}$) in serum beyond 30 days. However, lung tissue concentrations were significantly higher than those in the serum. At 24 hours, the mean concentration in lung tissue at least 3 days following the single injection. Serum titratable levels are a poor indicator of total body disposition. The lung/tissue concentration ratio in favor of lung tissue appeared to equilibrate by 3 days post-injection at approximately 60. In a study with radiolabeled Micotil[®], 90% of the dose was recovered from urine and feces respectively over 21 days. After a single subcutaneous injection of Micotil[®] at 10 mg/kg of body weight, micotil concentrations in excreted urine were found to be directly proportional to the amount of drug administered. Urine contained the highest clinical relevance of these findings has not been determined.

Microbiology: Tilmicosin has an in vitro antimicrobial spectrum that is predominantly Gram-positive with activity against Gram-negative bacilli. In vitro activity against several Mycoplasma species has also been observed. **Effectiveness:** In a multi-location field study, 1500 calves with naturally occurring BRD were treated with Micotil[®]. Responses to treatment were compared to saline-treated controls. A cure was defined as a calf with normal attitude and activity, normal respiration, and a rectal temperature of <104°F on Day 13. The cure rate was significantly higher (P=0.004) in Micotil-treated calves (85.1%) compared to saline-treated calves (29.2%). During the treatment phase of the trial, more than 10 BRD-related deaths in the Micotil-treated calves compared to 47 in the saline-treated calves.

Animal Safety: A safety study was conducted in feeder calves receiving subcutaneous doses of 25, 30, 40, or 50 mg/kg of Micotil[®] at 72-hour intervals. Deaths occurred in all groups. The incidence of death increased with increasing injection site swelling and mild hemorrhages at the injection sites were seen in animals in all dosage groups. Lesions were described as being grossly more severe and extensive in animals receiving higher dosages. Higher dosages resulted in more severe and extensive lesions. In addition, there were fewer deaths in the lower dosage groups. Lethality associated with the injection site was noted in two of twenty-four animals [one animal in the 30 mg/kg body weight treatment group and one animal in the 40 mg/kg treatment group]. No other drug related lesions were observed macroscopically or microscopically. Decreases in food and water consumption were noted in all treatment groups compared to the control group.

A separate safety study conducted in feeder calves, subcutaneous doses of 10, 30, or 50 mg/kg of body weight, injected 3 times at 72-hour intervals did not cause any deaths. Deaths occurred at the injection site. The only lesion observed was minimal necrosis at the injection site. Necrosis was minimal in animals dosed at 50 mg/kg. In an additional safety study, subcutaneous doses of 150 mg/kg body weight at 72-hour intervals resulted in death of two of the four treated animals. Edema was marked at the injection site. Minimal myocardial necrosis was the only lesion observed at necropsy. Death may have been observed with a single intramuscular dose of 5 mg/kg of body weight.

In sheep, single subcutaneous injections of 10 mg/kg body weight did not cause any deaths and no adverse effects of tilmicosin were observed on blood pressure, heart rate, or respiratory rate.

Toxicology: The heart is the target of toxicity of laboratory and domestic animals given Micotil[®] orally or parenterally routes. The primary cardiac effects are increased heart rate (tachycardia) and decreased contractility (negative inotropic effect). Cardiovascular toxicity may be due to calcium channel blockade.

Under subcutaneous injection, the acute median lethal dose of tilmicosin in mice is 97 mg/kg, and in rats is 185 mg/kg of body weight. Given orally, the median lethal dose is 800 mg/kg and 2250 mg/kg body weight in fasted and nonfasted rats, respectively. In dogs, the median lethal dose was 1.5 g/kg of body weight. In sheep, the median lethal dose was 1.5 g/kg of body weight. Intravenous cationic Mico-Inject-induced tachycardia and positive inotropic, restoring arterial pulse pressure. Dexamethasone partially offset the negative inotropic effects induced by Micotil[®] in dogs. β -adrenergic antagonists, such as propranolol, exacerbated the negative inotropic effects.

In monkeys, a single intramuscular dose of 10 mg/kg body weight caused no signs of toxicity. A single dose of 30 mg/kg body weight resulted in mortality and 30 mg/kg body weight caused the death of the only monkey tested. When a single intramuscular dose of 10 mg/kg body weight was given to a baboon, the baboon died. In a study with 20 mg/kg body weight caused mortality in 3 of 4 pigs, and 30 mg/kg caused the death of all 4 pigs tested. Injection of 4 to 5 and 5 to 6 mg/kg body weight intravenously followed by epinephrine, 1 mL (1:1000) intravenously 2 to 6 times, resulted in survival in 4 of 4 pigs tested. Pigs given 4 to 5 mg/kg body weight and 5 to 6 mg/kg body weight survived with no epinephrine all survived. These results suggest intravenous epinephrine may be contraindicated.

Results of genetic toxicity studies were all negative. Results of teratology and reproduction studies in rats were all negative. No reproductive toxicity was observed in rats or dogs after oral or subcutaneous administration of Micotil[®].

Storage Conditions: Store at or below 86° F (30°C). Protect from direct sunlight.

Store at 68° F (20°C), Preserved in 100 mL and 250 mL of the 2 solar design.